These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 8643695)

  • 1. The treatment of chronic progressive multiple sclerosis with cladribine.
    Beutler E; Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1716-20. PubMed ID: 8643695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of cladribine treatment in multiple sclerosis.
    Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J; Beutler E
    Mult Scler; 1996 Jul; 1(6):343-7. PubMed ID: 9345414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cladribine in treatment of chronic progressive multiple sclerosis.
    Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J; Beutler E
    Lancet; 1994 Jul; 344(8914):9-13. PubMed ID: 7912347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group.
    Rice GP; Filippi M; Comi G
    Neurology; 2000 Mar; 54(5):1145-55. PubMed ID: 10720289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis.
    Selby R; Brandwein J; O'Connor P
    Can J Neurol Sci; 1998 Nov; 25(4):295-9. PubMed ID: 9827230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis.
    Romine JS; Sipe JC; Koziol JA; Zyroff J; Beutler E
    Proc Assoc Am Physicians; 1999; 111(1):35-44. PubMed ID: 9893155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
    Giovannoni G; Comi G; Cook S; Rammohan K; Rieckmann P; Soelberg Sørensen P; Vermersch P; Chang P; Hamlett A; Musch B; Greenberg SJ;
    N Engl J Med; 2010 Feb; 362(5):416-26. PubMed ID: 20089960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of multiple sclerosis and other autoimmune diseases with cladribine.
    Beutler E; Sipe J; Romine J; McMillan R; Zyroff J; Koziol J
    Semin Hematol; 1996 Jan; 33(1 Suppl 1):45-52. PubMed ID: 8714617
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study.
    Stelmasiak Z; Solski J; Nowicki J; Jakubowska B; Ryba M; Grieb P
    Mult Scler; 2009 Jun; 15(6):767-70. PubMed ID: 19482866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
    Comi G; Cook SD; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett AC; Viglietta V; Greenberg SJ
    J Neurol; 2013 Apr; 260(4):1136-46. PubMed ID: 23263473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
    Janiec K; Wajgt A; Kondera-Anasz Z
    Med Sci Monit; 2001; 7(1):93-8. PubMed ID: 11208501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
    Giovannoni G; Galazka A; Schick R; Leist T; Comi G; Montalban X; Damian D; Dangond F; Cook S
    Drug Saf; 2020 Jul; 43(7):635-643. PubMed ID: 32447743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recommendations for the use of cladribine tablets in recurring multiple sclerosis].
    Oreja-Guevara C; García-Merino JA; Saiz A; Rodríguez-Antigüedad A; Álvarez-Cermeño JC; Estrada-Pérez V; Izquierdo G; Fernández O
    Rev Neurol; 2019 Dec; 69(s02):1-9. PubMed ID: 31933293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
    Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan K; Rieckmann P; Comi G; Dangond F; Adeniji AK; Vermersch P
    Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients.
    Adams HP; Wagner S; Sobel DF; Slivka LS; Sipe JC; Romine JS; Beutler E; Koziol JA
    Eur Neurol; 1999 Jul; 42(1):52-63. PubMed ID: 10394049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cladribine in aggressive forms of multiple sclerosis.
    Martinez-Rodriguez JE; Cadavid D; Wolansky LJ; Pliner L; Cook SD
    Eur J Neurol; 2007 Jun; 14(6):686-9. PubMed ID: 17539951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of repeated treatments with cladribine (2-chlorodeoxyadenosine) on blood counts in multiple sclerosis patients.
    Grieb P; Stelmasiak Z; Solski J; Nowicki J; Jakubowska B; Ryba M
    Arch Immunol Ther Exp (Warsz); 1995; 43(5-6):323-7. PubMed ID: 8744654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cladribine: mechanisms and mysteries in multiple sclerosis.
    Jacobs BM; Ammoscato F; Giovannoni G; Baker D; Schmierer K
    J Neurol Neurosurg Psychiatry; 2018 Dec; 89(12):1266-1271. PubMed ID: 29991490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
    Leist TP; Comi G; Cree BA; Coyle PK; Freedman MS; Hartung HP; Vermersch P; Casset-Semanaz F; Scaramozza M;
    Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.